Yes, COVID-19 can cause back pain, and it does so through at least four distinct routes: direct viral inflammation of muscle and joint tissue, immune-signaling pain sensitization, mechanical strain from coughing and bed rest, and post-illness syndromes that outlast the infection itself. Back pain is one of the more commonly reported musculoskeletal symptoms during acute COVID-19, typically appearing alongside fever, fatigue, and myalgia in the first week of illness. It is rarely the only symptom and rarely the first. The more useful question is not whether the virus can produce back pain but which mechanism applies to a given case, because the mechanisms carry very different timelines and very different red flags.
How the virus plausibly reaches muscle and joint tissue
The deep mechanism starts with the angiotensin-converting enzyme 2 (ACE2) receptor. SARS-CoV-2 docks onto ACE2 to enter cells, and ACE2 is expressed in skeletal muscle, synovial fibroblasts, and vascular endothelium, not just in the airway. When the virus enters these tissues, the local immune response releases interleukin-6 (IL-6), tumor necrosis factor alpha (TNF-alpha), and other cytokines. These mediators sensitize nociceptors, the pain-sensing nerve endings in muscle and fascia, lowering their firing threshold. The result is a deep, diffuse, aching pain that patients often describe as "bone pain" rather than sharp or positional pain.
A second layer involves the innate immune system more broadly. Circulating viral RNA engages Toll-like receptors on immune cells, triggering prostaglandin synthesis and a systemic inflammatory state. Prostaglandins sensitize pain fibers throughout the body, which is why myalgia and back pain cluster with fever and fatigue rather than appearing in isolation. The pain is a byproduct of immune signaling, not necessarily of tissue damage.
Plain language: the virus does not have to chew into a disc or a vertebra to make the back hurt. It can inflame and sensitize muscle and connective tissue through the immune response it triggers.
How common back pain actually is during acute infection
Quantifying the symptom is messier than headlines suggest. Systematic reviews of early-pandemic cohorts consistently place myalgia and arthralgia among the most frequent extrapulmonary symptoms, reported in roughly 15 to 45 percent of hospitalized and non-hospitalized patients depending on the cohort and case definition. Back pain specifically is usually reported as a subset of myalgia rather than as a standalone variable, which inflates uncertainty.
A widely cited meta-analysis of early COVID-19 cohorts found myalgia in approximately one-third of patients, with back pain and low back pain appearing in smaller fractions, often under 15 percent when reported separately. The wide range reflects three real problems: inconsistent definitions (myalgia versus arthralgia versus back pain), recall bias in outpatient surveys, and the fact that early cohorts were skewed toward hospitalized patients with more severe disease.
Context matters for interpretation. Back pain prevalence in the general adult population over any four-week window is also substantial, so some overlap during a COVID-19 illness is coincidental. The signal that back pain is COVID-related comes from its clustering with other inflammatory symptoms and its timing relative to infection onset, not from raw prevalence alone.
The timeline: when back pain appears and how long it lasts
| Phase | Typical timing | Pain character | What it usually reflects |
|---|---|---|---|
| Incubation | Days 0-5 after exposure | None | No symptoms yet |
| Acute inflammatory | Days 1-7 of symptoms | Diffuse ache, myalgia, fever-associated | Cytokine-driven sensitization |
| Peak illness | Days 5-10 | Deep ache, worse with coughing | Mechanical strain plus inflammation |
| Early recovery | Weeks 1-4 | Fading, intermittent | Resolving inflammation |
| Post-acute | Beyond 4 weeks | Variable, often mechanical | Deconditioning, post-viral syndrome |
| Post-COVID (PASC) | Beyond 12 weeks | Persistent, sometimes neuropathic | Central sensitization, other drivers |
The timeline is the single most useful diagnostic frame. Back pain that begins in the first week and tracks with fever and fatigue fits the inflammatory mechanism. Back pain that appears or persists beyond four weeks after other symptoms resolve points toward deconditioning or post-acute sequelae, which have different management.
Edge cases where back pain signals something more serious
The counterintuitive caveat: back pain during COVID-19 is almost always benign myalgia, but the pandemic created conditions in which dangerous causes of back pain became more common and were missed. Prolonged immobility during severe illness raises the risk of vertebral compression fractures in patients with osteoporosis, and case reports document this in patients who spent weeks bedbound. Deep vein thrombosis and pulmonary embolism can present with back or flank pain, particularly in patients who were hospitalized or immobile.
In children and adolescents, back pain accompanying fever warrants attention for discitis or vertebral osteomyelitis, which are rare but treatable. In adults, back pain with fever and new neurological symptoms raises concern for spinal epidural abscess, a condition where delayed diagnosis is costly.
Seek urgent evaluation for back pain with any of these features:
Fever above 100.4 F (38 C) with new focal spinal tenderness New weakness, numbness, or bowel/bladder dysfunction Pain that wakes you from sleep and does not change with position Back pain after a fall, even a minor one, in someone with known osteoporosis Progressive pain over days with no improvement, especially with night sweats History of cancer, intravenous drug use, or recent spinal procedure
These bullets are red flags, not a diagnosis. They describe patterns where imaging and examination should happen quickly rather than after weeks of home management.
Common misconceptions about COVID and back pain
Misconception one: back pain proves the virus invaded spinal tissue. It does not. In most cases the pain is a systemic inflammatory effect, and direct viral involvement of muscle or joint is uncommon and not routinely demonstrable.
Misconception two: if back pain is a COVID symptom, then any back pain during a COVID wave is COVID. Timing and clustering matter. Isolated mechanical back pain after lifting a heavy box is still mechanical back pain.
Misconception three: post-COVID back pain means permanent damage. Most post-acute musculoskeletal symptoms improve with graded activity, though recovery can take months. Persistent pain after viral illness is often driven by central sensitization and deconditioning rather than ongoing tissue injury.
Misconception four: imaging will explain the pain. In the absence of red flags, early MRI or CT for back pain rarely changes management and frequently finds age-related changes that are unrelated to symptoms. This is true in COVID-era back pain as much as any other.
What to do: practical steps and thresholds
For acute back pain during a COVID-19 illness, the priorities are comfort, safe movement, and monitoring for red flags. Acute inflammatory back pain usually eases as the fever and systemic symptoms resolve, typically over one to three weeks.
Specific steps:
Keep moving gently. Prolonged bed rest worsens stiffness and deconditioning. Short walks and position changes every hour are better than stillness. Use heat and simple analgesia as directed by a clinician. Avoid combining multiple products containing the same active ingredient. Reassess at 72 hours. If pain is worsening rather than plateauing, or if new neurological symptoms appear, contact a clinician. Screen for red flags daily during the first two weeks, especially if there is fever, night pain, or weakness. After the acute illness, resume activity in graded increments. If pain persists beyond four weeks, a structured physical therapy assessment is reasonable. Do not treat persistent post-COVID back pain with prolonged rest. Graded exposure to movement is the evidence-supported approach for non-specific back pain.
The threshold to remember: four weeks. Pain that has not begun to improve by four weeks after acute illness deserves clinical assessment rather than continued watchful waiting, because it may reflect post-acute sequelae, deconditioning, or an unrelated cause that coincided with the infection.
What the evidence can and cannot tell us
The honest limitation: most studies of COVID-19 and back pain are observational, retrospective, and heterogeneous in how they define the symptom. Causal attribution is difficult because back pain is common, and because COVID-19 cohorts rarely include a matched comparison group with another respiratory illness. The best conclusion supported by the data is that back pain is a frequent but non-specific accompaniment of acute COVID-19 and that persistent back pain after infection exists but its mechanisms are incompletely characterized.
Important caveats include the possibility of reporting bias in surveys, the confounding of back pain with fever and systemic illness, and the absence of imaging-confirmed tissue pathology in most reported cases. The distinction between inflammatory myalgia and mechanical back pain matters clinically, and current evidence supports treating the former as self-limited and the latter with activity and, if persistent, formal assessment.
What the evidence does not support: that COVID-19 specifically targets the spine, that back pain is a reliable diagnostic sign, or that post-COVID back pain requires prolonged rest. The mechanisms are plausible and partially documented; the clinical guidance is conservative and activity-based. Treat back pain during COVID-19 the way you would treat most acute back pain, with added vigilance for red flags during the inflammatory phase, and escalate if it persists beyond four weeks.